帕博利珠单抗联合厄洛替尼或吉非替尼一线治疗携带敏感性EGFR突变的晚期非小细胞肺癌
KEYNOTE-021 1/2期研究评估帕博利珠单抗联合厄洛替尼或吉非替尼一线治疗晚期EGFR突变NSCLC。帕博利珠单抗联合厄洛替尼可行,未出现剂量限制性毒性或5级事件;联合吉非替尼因5/7例(71.4%)出现3/4级肝毒性而不可行。联合厄洛替尼的客观缓解率为41.7%,未较既往单药研究提高。
要点
- 帕博利珠单抗联合厄洛替尼未出现剂量限制性毒性或5级事件,不良事件与单药预期相似。
- 帕博利珠单抗联合吉非替尼因5/7例(71.4%)出现3/4级肝毒性而不可行,4例永久停药。
- 联合厄洛替尼的客观缓解率为41.7%,PD-L1表达≥50%的4例患者均缓解。
核心结论
- 帕博利珠单抗联合吉非替尼不可行,但帕博利珠单抗联合厄洛替尼的毒性特征提示免疫治疗与抗EGFR治疗联合可行。
- 帕博利珠单抗联合厄洛替尼未较既往单药研究提高客观缓解率,需进一步评估对其他疗效结局的潜在影响。
研究设计与样本
- 1/2期KEYNOTE-021研究(NCT02039674),采用3+3设计并队列扩展。
- 入组既往未治疗的IIIB/IV期EGFR突变NSCLC成人患者,E队列接受帕博利珠单抗2 mg/kg静脉每3周联合口服厄洛替尼150 mg每日,F队列接受帕博利珠单抗联合口服吉非替尼250 mg每日。
- E队列12例,F队列7例;主要目标为确定推荐的2期剂量。
- 肿瘤反应按RECIST 1.1由盲法独立中心审查评估。
主要发现
- 未发生剂量限制性毒性或5级事件。
- 帕博利珠单抗联合厄洛替尼可行,不良事件与单药预期相似。
- 帕博利珠单抗联合吉非替尼不可行,7例中5例(71.4%)出现3/4级肝毒性,4例永久停止治疗。
- 帕博利珠单抗联合厄洛替尼最常见的治疗相关不良事件为皮疹(50.0%),皮炎痤疮样、腹泻、甲状腺功能减退和瘙痒各占33.3%。
- 客观缓解率为41.7%,包括PD-L1表达≥50%的4例患者均缓解。
关键数值与推荐
- 帕博利珠单抗联合厄洛替尼的客观缓解率为41.7%。
- 帕博利珠单抗联合吉非替尼的3/4级肝毒性发生率为5/7例(71.4%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anti-EGFR agents are standard treatments for patients with EGFR-mutant advanced NSCLC. The feasibility of combining erlotinib or gefitinib with the anti-programmed death 1 immunotherapy pembrolizumab was evaluated in the phase 1/2 KEYNOTE-021 study (NCT02039674). METHODS: Adults with previously untreated stage IIIB/IV EGFR-mutant NSCLC were treated with pembrolizumab 2 mg/kg intravenously every 3 weeks plus oral erlotinib 150 mg daily in cohort E or oral gefitinib 250 mg daily in cohort F, using a 3 + 3 design with cohort expansion. rTumor response was evaluated per Response Evaluation Criteria in Solid Tumors version 1.1 by blinded independent central review. The primary objective was determination of a recommended phase 2 dose. RESULTS: Twelve patients enrolled to receive pembrolizumab plus erlotinib and seven to receive pembrolizumab plus gefitinib. No dose-limiting toxicities or grade 5 events occurred. Pembrolizumab plus erlotinib was feasible, with adverse events similar to those expected for monotherapy. However, pembrolizumab plus gefitinib was not feasible due to grade 3/4 liver toxicity in five of seven patients (71.4%), leading to permanent treatment discontinuation in four patients. The most frequently occurring treatment-related adverse events with pembrolizumab plus erlotinib were rash (50.0%), dermatitis acneiform, diarrhea, hypothyroidism, and pruritus (33.3% each). The objective response rate was 41.7%, including response in all four patients with programmed death ligand 1 expression 50% or greater. CONCLUSIONS: Although pembrolizumab plus gefitinib was not feasible, the toxicity profile observed with pembrolizumab plus erlotinib suggests combining immunotherapy with anti-EGFR therapy is feasible. Pembrolizumab plus erlotinib did not improve objective response rate compared with previous monotherapy studies; further evaluation would be necessary to evaluate potential effects on other efficacy outcomes.
引用
- Yang JC, Gadgeel SM, Sequist LV, et al. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 2018. PMID: 30529597. doi:10.1016/j.jtho.2018.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。